EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins

Giovanni Vitale, Ilona Rybinska, Giulia Arrivi, Vincenzo Marotta, Gianfranco Di Iasi, Alessia Filice, Christopher Nardi, Annamaria Colao, Antongiulio Faggiano, NIKE Group

Neuroendocrinology · 2025

DOI: 10.1159/000543953 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuroendocrinology, 2025. Verfasst von Giovanni Vitale und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS - Istituto Auxologico Italiano, Milan, Italy. Hauptthemen laut MEDLINE: Anilides, Neuroendocrine Tumors, Pyridines, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors arising from neuroendocrine cells, exhibiting a wide range of behaviors from indolent to highly aggressive forms. Treatment options remain limited, particularly for progressive cases. Cabozantinib, a multitarget tyrosine kinase inhibitor, has demonstrated potential in targeting key pathways related to tumor growth, angiogenesis, and metastasis. Summary: This review provides a comprehensive analysis of cabozantinib’s therapeutic role across various NEN subtypes, including gastroenteropancreatic NENs, lung NENs, pheochromocytomas/paragangliomas, Merkel cell carcinoma, presacral NENs, pituitary neuroendocrine tumors, and neuroendocrine prostate cancer. Key Messages: The paper discusses several preclinical and clinical studies that demonstrate the efficacy of cabozantinib in slowing tumor progression and improving progression-free survival, particularly in patients with progressive, well-differentiated NENs. However, cabozantinib’s complex toxicity profile limits its broad application, necessitating further research to optimize dosing, particularly in syndromic NENs. Ongoing trials are investigating cabozantinib in combination with somatostatin analogs, peptide receptor radionuclide therapy, temozolomide, and immunotherapies in order to overcome treatment resistance and expanding therapeutic strategies for advanced NENs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesNeuroendocrine TumorsPyridinesAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimals

Stichwörter der Autor:innen

CabozantinibNeuroendocrine carcinomaNeuroendocrine neoplasmsNeuroendocrine tumorsTyrosine kinase inhibitors

Substanzen

cabozantinibAnilidesPyridinesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS - Istituto Auxologico Italiano, Milan, Italy.
  • Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
  • Oncology Unit, Department of Clinical and Molecular Medicine, Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  • Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Zitieren

APA

Vitale, G., Rybinska, I., Arrivi, G., Marotta, V., Di Iasi, G., Filice, A., Nardi, C., Colao, A., Faggiano, A., & NIKE Group (2025). Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins. Neuroendocrinology. https://doi.org/10.1159/000543953

Vancouver

Vitale G, Rybinska I, Arrivi G, Marotta V, Di Iasi G, Filice A, et al. Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins. Neuroendocrinology. 2025. doi:10.1159/000543953

BibTeX
@article{Vitale2025,
  author = {Vitale, Giovanni and Rybinska, Ilona and Arrivi, Giulia and Marotta, Vincenzo and Di Iasi, Gianfranco and Filice, Alessia and Nardi, Christopher and Colao, Annamaria and Faggiano, Antongiulio and NIKE Group, NIKE Group},
  title = {Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins},
  journal = {Neuroendocrinology},
  year = {2025},
  doi = {10.1159/000543953}
}
Kostenlos starten →